<p><strong>BACKGROUND</strong>: Deep vein thrombosis (DVT) is a relatively prevalent disease which causes high costs due to the required diagnostic tests, specialized treatments, and hospital admission. In recent decades, implementation of thromboprophylaxis protocols has significantly reduced the incidence of thromboembolism in hospitals. The present study aimed to compare the incidence of venous thromboembolism before and after implementation of the mentioned protocol in hospital with identified risk factors and underlying diseases.</p> <p><strong>METHODS</strong>: In this case-control group, 385 patients at the risk of DVT, some before and some after implementation of the protocol, were studied. Therefore, the level of thromboprophylaxis...
Pharmacological prophylaxis of venous thromboembolism (VTE) is recommended for medical inpatients. S...
INTRODUCTION: DVT or pulmonary embolism may occur in almost 2 in 1000 people each year, with up to 2...
VTE, encompassing DVT and pulmonary embo-lism (PE) is common, with an incidence of one in 1,000, and...
CONTEXT: Deep vein thrombosis (DVT) is a serious, common disease whose complications include pulmon...
Objective: A systematic review and meta-analysis was performed to determine the role of thromboproph...
The last 50 years have witnessed a multitude of publications evaluating the efficacy, safety and cos...
It is unclear whether thromboprophylaxis produces a consistent risk reduction in different subgroups...
The 7th conference of the American College of Chest Physicians (ACCP7) provides recommendations on t...
Pharmacological prophylaxis of venous thromboembolism (VTE) is recommended for medical inpatients. S...
We prospectively assessed the implementation of venous thromboembolism (VTE) prophylaxis guidelines ...
Objectives: To assess the benefits in terms of reductions in the risks of deep vein thrombosis (DVT...
Objectives: To assess the benefits in terms of reductions in the risks of deep vein thrombosis (DVT)...
Thrombolytic therapy might reduce venous thromboembolism-related mortality and morbidity, but it cou...
Pharmacological prophylaxis of venous thromboembolism (VTE) is recommended for medical inpatients. S...
INTRODUCTION: DVT or pulmonary embolism may occur in almost 2 in 1000 people each year, with up to 2...
VTE, encompassing DVT and pulmonary embo-lism (PE) is common, with an incidence of one in 1,000, and...
CONTEXT: Deep vein thrombosis (DVT) is a serious, common disease whose complications include pulmon...
Objective: A systematic review and meta-analysis was performed to determine the role of thromboproph...
The last 50 years have witnessed a multitude of publications evaluating the efficacy, safety and cos...
It is unclear whether thromboprophylaxis produces a consistent risk reduction in different subgroups...
The 7th conference of the American College of Chest Physicians (ACCP7) provides recommendations on t...
Pharmacological prophylaxis of venous thromboembolism (VTE) is recommended for medical inpatients. S...
We prospectively assessed the implementation of venous thromboembolism (VTE) prophylaxis guidelines ...
Objectives: To assess the benefits in terms of reductions in the risks of deep vein thrombosis (DVT...
Objectives: To assess the benefits in terms of reductions in the risks of deep vein thrombosis (DVT)...
Thrombolytic therapy might reduce venous thromboembolism-related mortality and morbidity, but it cou...
Pharmacological prophylaxis of venous thromboembolism (VTE) is recommended for medical inpatients. S...
INTRODUCTION: DVT or pulmonary embolism may occur in almost 2 in 1000 people each year, with up to 2...
VTE, encompassing DVT and pulmonary embo-lism (PE) is common, with an incidence of one in 1,000, and...